Myeloma Paper of the Day, June 13th, suggested by Robert Orlowski
Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: German analysis of 343 triple-class exposed relapsed/refractory patients who received ide-cel or cilta-cel finds cilta with higher CR rate (61% vs. 39%) and improved response conversion with more CRs after starting from <CR pre-CAR.”
Title: Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST
Authors: Maximilian Merz, Nico Gagelmann, Samih Smaili, Sarah Flossdorf, Sandra Sauer, Christof Scheid, Bastian von Tresckow, Gerald Georg Wulf, Katja C Weisel, Igor Blau, Monika Engelhardt, Ralph Wäsch, Natalie Schub, Raphael Teipel, Judith S. Hecker, Johannes M. Waldschmidt, Britta Besemer, Ben-Niklas Baermann, Simon Call, Leo Hansmann, Francis Ayuketang Ayuk, Marc S. Raab, Hermann Einsele, Uwe Platzbecker, Nicolaus Kröger
You can read the Full Article in Blood.
More posts featuring Robert Orlowski.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023